These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18093264)

  • 21. Early cyclosporine a withdrawal in kidney transplant recipients under a sirolimus-based immunosuppressive regimen: pathological study of graft biopsies at 1-year posttransplant.
    Ruiz JC; Campistol JM; Mota A; Prats D; Gutiérrez A; Castro A; Pinto JR; García J; Morales JM; Grinyo JM; Arias M
    Transplant Proc; 2002 Feb; 34(1):92-3. PubMed ID: 11959199
    [No Abstract]   [Full Text] [Related]  

  • 22. A pilot study of cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
    Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H
    Transplant Proc; 2000 Dec; 32(8):2778. PubMed ID: 11134800
    [No Abstract]   [Full Text] [Related]  

  • 23. Steroid-free immunosuppression in organ transplantation.
    Luo G; Falta EM; Elster EA
    Curr Diab Rep; 2005 Aug; 5(4):305-10. PubMed ID: 16033684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of immunosuppressive therapy on graft half-life projections. The Collaborative Transplant Study.
    Opelz G
    Transplant Proc; 1999 Nov; 31(7A):31S-33S. PubMed ID: 10576040
    [No Abstract]   [Full Text] [Related]  

  • 25. Persistent proteinuria as a prognostic factor for determining long-term graft survival in renal transplant recipients.
    Park JH; Park JH; Bok HJ; Kim BS; Yang CW; Kim YS; Kim SY; Moon IS; Koh YB; Bang BK
    Transplant Proc; 2000 Nov; 32(7):1924. PubMed ID: 11120002
    [No Abstract]   [Full Text] [Related]  

  • 26. Randomized trial of tacrolimus in combination with mycophenolate mofetil versus cyclosporine with mycophenolate mofetil in cadaveric renal transplant recipients with delayed graft function.
    Liu B; Lin ZB; Ming CS; Zhang WJ; Chen ZS; Sha B; Zeng FJ; Chen S
    Transplant Proc; 2003 Feb; 35(1):87-8. PubMed ID: 12591319
    [No Abstract]   [Full Text] [Related]  

  • 27. Advances in immunosuppression for renal transplantation.
    Durrbach A; Francois H; Beaudreuil S; Jacquet A; Charpentier B
    Nat Rev Nephrol; 2010 Mar; 6(3):160-7. PubMed ID: 20125095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Deoxyspergualin on the long-term outcome of renal transplantation.
    Tanabe K; Tokumoto T; Ishikawa N; Shimizu T; Okuda H; Ito S; Shimmura H; Inui M; Harano M; Ohtsubo S; Manu M; Shiroyanagi Y; Yagisawa T; Fuchinoue S; Toma H
    Transplant Proc; 2000 Nov; 32(7):1745-6. PubMed ID: 11119916
    [No Abstract]   [Full Text] [Related]  

  • 29. Tacrolimus versus cyclosporine as primary prophylactic therapy after cadaveric renal transplant: two-year survival study.
    Wong KM; Cheung CY; Chan YH; Chak WL; Choi KS; Chau KF; Li CS
    Transplant Proc; 2000 Nov; 32(7):1721-2. PubMed ID: 11119907
    [No Abstract]   [Full Text] [Related]  

  • 30. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group.
    Jensik SC
    Transplant Proc; 1998 Jun; 30(4):1216-8. PubMed ID: 9636494
    [No Abstract]   [Full Text] [Related]  

  • 31. Future immunosuppressive agents in solid-organ transplantation.
    Gabardi S; Cerio J
    Prog Transplant; 2004 Jun; 14(2):148-56. PubMed ID: 15264459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation.
    Groth CG; Brattström C; Claesson K; Bäckman L
    Transplant Proc; 1998 Dec; 30(8):4064-5. PubMed ID: 9865296
    [No Abstract]   [Full Text] [Related]  

  • 33. Primary tacrolimus-based immunosuppression in renal allograft recipients: a single center experience.
    Lye WC
    Transplant Proc; 2000 Nov; 32(7):1700-1. PubMed ID: 11119898
    [No Abstract]   [Full Text] [Related]  

  • 34. Tacrolimus versus cyclosporine in primary simultaneous pancreas-kidney transplantation: preliminary results at 1 year of a large multicenter trial.
    Land W; Malaise J; Sandberg J; Langrehr J;
    Transplant Proc; 2002 Aug; 34(5):1911-2. PubMed ID: 12176625
    [No Abstract]   [Full Text] [Related]  

  • 35. [What happens to a child after kidney transplant?].
    Qvist E; Rönnholm K; Holmberg C
    Duodecim; 2006; 122(2):197-9. PubMed ID: 16509068
    [No Abstract]   [Full Text] [Related]  

  • 36. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group.
    Miller J; Pirsch JD; Deierhoi M; Vincenti F; Filo RS
    Transplant Proc; 1997; 29(1-2):304-5. PubMed ID: 9123008
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunosuppression strategies in developing countries.
    Naqvi SA
    Transplant Proc; 2002 Sep; 34(6):2083-4. PubMed ID: 12270322
    [No Abstract]   [Full Text] [Related]  

  • 38. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up.
    Citterio F; Scatà MC; Romagnoli J; Pozzetto U; Nanni G; Castagneto M
    Transplant Proc; 2002 Aug; 34(5):1685-6. PubMed ID: 12176535
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation.
    El-Nachef N; Terdiman J; Mahadevan U
    Am J Gastroenterol; 2010 May; 105(5):1210-1. PubMed ID: 20445523
    [No Abstract]   [Full Text] [Related]  

  • 40. Trial of steroid withdrawal in renal transplant recipients with long-term--surviving allograft.
    Mizuno Y; Kikuchi H; Fujimori K; Doi H; Orii T; Ohkohchi N; Satomi S
    Transplant Proc; 2000 Nov; 32(7):1677-8. PubMed ID: 11119888
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.